Ionis wins FDA approval for zanvastro targeting rare brain disease
Ionis Pharmaceuticals received regulatory approval for zanvastro (Zilganersen) to treat a rare brain disease in both adult and pediatric patients. The news is getting a muted market reaction.
Ionis Pharmaceuticals has won regulatory approval for a first-of-its-kind drug targeting a rare brain disease, though Wall Street is shrugging off the news for a simple reason. Zilganersen, branded as Zanvastro, has been approved to treat both adult and pediatric patients with Ale…